CSOP Hang Seng Biotech ETF (03174.HK) has shown strong performance at the start of the year, with a cumulative increase of over 10%! Its gain ranks among the top in the Hong Kong stock ETF market today.

NewTimeSpace News: According to Wind data, as of 14:11 on January 7, 2026,CSOP Hang Seng Biotech ETF (03174.HK) has risen by 2.61%. It has performed strongly since the beginning of the year, with a cumulative increase of over 10%.

CSOP Hang Seng Biotech ETF (03174.HK) is a Hong Kong stock ETF managed by CSOP Asset Management, closely tracking the Hang Seng Biotechnology Index and covering leading biotech companies listed in Hong Kong such as WuXi Biologics and BeiGene.

NewTimeSpace Research suggests that this product is suitable for investors who are optimistic about biotech sectors such as innovative drugs and gene therapy in the long term, can withstand high volatility, and have access to the Stock Connect investment channel. It is especially suitable for diversifying risks and capturing industry growth dividends through methods like regular fixed investments.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.